David G. Standaert mainly focuses on Neuroscience, Cell biology, Internal medicine, Metabotropic glutamate receptor and Endocrinology. His Neuroscience study frequently draws parallels with other fields, such as Glutamate receptor. His Cell biology study combines topics from a wide range of disciplines, such as Trinucleotide repeat expansion, Microglia, Neuroinflammation, Pars compacta and Proinflammatory cytokine.
David G. Standaert has researched Internal medicine in several fields, including Gene expression, Gene expression profiling and Atriopeptins. As part of the same scientific family, he usually focuses on Endocrinology, concentrating on NMDA receptor and intersecting with Dopamine. He works mostly in the field of Levodopa, limiting it down to topics relating to Anesthesia and, in certain cases, Disease, as a part of the same area of interest.
His main research concerns Neuroscience, Parkinson's disease, Internal medicine, Disease and Endocrinology. When carried out as part of a general Parkinson's disease research project, his work on Dyskinesia, Levodopa and Levodopa carbidopa is frequently linked to work in In patient, therefore connecting diverse disciplines of study. His specific area of interest is Internal medicine, where David G. Standaert studies Progressive supranuclear palsy.
His Disease research integrates issues from Biomarker, Physical therapy and Clinical trial, Bioinformatics. David G. Standaert studies Dopaminergic which is a part of Endocrinology. His Substantia nigra research includes elements of Molecular biology and Cell biology.
His primary scientific interests are in Parkinson's disease, Disease, Internal medicine, Neuroscience and Progressive supranuclear palsy. His study in Parkinson's disease is interdisciplinary in nature, drawing from both Anesthesia and Observational study. David G. Standaert combines subjects such as Confounding, Clinical trial and Immunology, Pathogenesis with his study of Disease.
The concepts of his Internal medicine study are interwoven with issues in Endocrinology, Neurology and Rating scale. His research on Endocrinology focuses in particular on Dopaminergic. His Neuroscience study frequently links to other fields, such as Precision medicine.
His scientific interests lie mostly in Parkinson's disease, Disease, Neuroscience, Internal medicine and Adverse effect. His Parkinson's disease research is multidisciplinary, incorporating elements of Neuroprotection, Drug and Pharmacology. His research in Disease intersects with topics in Clinical trial, Pathogenesis, Postmortem studies, Neurology and Confounding.
His Neuroscience study often links to related topics such as Precision medicine. The study of Internal medicine is intertwined with the study of Endocrinology in a number of ways. His biological study deals with issues like Dyskinesia, which deal with fields such as Anesthesia and Movement disorders.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Pramipexole vs Levodopa as initial treatment for Parkinson disease: A randomized controlled trial
R. Holloway;I. Shoulson;K. Kieburtz;M. McDermott.
JAMA (2000)
The Parkinson Progression Marker Initiative (PPMI)
Kenneth Marek;Danna Jennings;Shirley Lasch;Andrew Siderowf.
Progress in Neurobiology (2011)
Sp1 and TAFII130 Transcriptional Activity Disrupted in Early Huntington's Disease
Anthone W. Dunah;Hyunkyung Jeong;April Griffin;Yong Man Kim.
Science (2002)
Monitoring Motor Fluctuations in Patients With Parkinson's Disease Using Wearable Sensors
S. Patel;K. Lorincz;R. Hughes;N. Huggins.
international conference of the ieee engineering in medicine and biology society (2009)
A(2A) adenosine receptor deficiency attenuates brain injury induced by transient focal ischemia in mice
J.-F. Chen;Zhihong Huang;Jianya Ma;Jinmin Zhu.
The Journal of Neuroscience (1999)
Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial.
Robert G Holloway;Ira Shoulson;Stanley Fahn;Karl Kieburtz.
JAMA Neurology (2004)
Metabotropic glutamate receptor mRNA expression in the basal ganglia of the rat
CM Testa;DG Standaert;AB Young;JB Penney.
The Journal of Neuroscience (1994)
Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study.
C Warren Olanow;Karl Kieburtz;Per Odin;Alberto J Espay.
Lancet Neurology (2014)
Molecular markers of early Parkinson's disease based on gene expression in blood
Clemens R. Scherzer;Clemens R. Scherzer;Aron C. Eklund;Lee J. Morse;Zhixiang Liao.
Proceedings of the National Academy of Sciences of the United States of America (2007)
Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy
J.A. Obeso;M. Stamelou;M. Stamelou;C.G. Goetz;W. Poewe.
Movement Disorders (2017)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:
Harvard University
University of California, San Diego
Harvard University
Cleveland Clinic
Baylor College of Medicine
Harvard University
Beth Israel Deaconess Medical Center
University of California, San Francisco
University of Toronto
Harvard University
Steklov Mathematical Institute
Nanjing University of Posts and Telecommunications
Georgia Institute of Technology
École Polytechnique Fédérale de Lausanne
Karlsruhe Institute of Technology
Åbo Akademi University
University of Florida
University of Virginia
National Institutes of Health
Universidade de São Paulo
University of Erlangen-Nuremberg
University of Pennsylvania
Transylvania University of Brașov
University of Pisa
Indiana University
Indiana University